article 3 months old

RESEARCH: Abundant Produce, The Seeds Of Greatness

FYI | Sep 19 2019

An Innovative Nutraceutical Company

By Pitt Street Research

Abundant Produce Ltd ((ABT)) is a Sydney-based life sciences company focused on the Abundant Natural Health brand, a range of scientifically validated, Over-The-Counter nutraceutical products utilising 100% natural biologics and minerals to provide relief from pain and inflammation.

Abundant Produce's foundational business was Abundant Seeds, which uses cutting edge science to breed novel vegetable varieties for sale to the horticulture industry. This business is now considered non-core.

The market opportunities are significant

Abundant is currently gathering clinical data for two key indications, one in pain and one in psoriasis. Should the data be favourable there is substantial potential for OTC sales, as well as potentially moving to more prescription-type indications. Abundant Natural Health continues to develop its distribution channels, with; growing Australian pharmacy uptake; US warehousing to service Amazon sales, a US retail strategy in development; and a multi-channel China cross-border strategy including mainland bonded warehousing. All ease the path to consumers.

There is potential to extract value from Abundant Seeds

There is potential to extract value from Abundant Seeds, with the business now selling cucumber seeds, and growers trialing tomato seeds, followed by eggplant, zucchini and capsicum in the product pipeline. In 2019 management has taken the strategic decision to investigate selling this business, taking advantage of international industry appetite for intellectual property related to vegetable plants.

Abundant is funded for the next stage of its growth

A recent SPP at 6 cents per share raised $1.3m, with all directors participating, and Executive Director and General Manager Tony Crimmins taking his holding to 19.9%.

Valuation range of $0.13–0.23 per share

We value Abundant at 13 cents per share base case and 23 cents per share optimistic case using a DCF-based valuation approach. We see Abundant potentially re-rating towards our valuation range as trial data emerges confirming the effectiveness of new Abundant Natural Health products, and as sales commence for those new products.

Download the full report

Earlier today the report above was released by Pitt Street Research for which FNArena is a partner in distribution. The full report can be accessed here:

https://www.fnarena.com/index.php/pitt-street-research/ABT/

Find out why FNArena subscribers like the service so much: "Your Feedback (Thank You)" – Warning this story contains unashamedly positive feedback on the service provided.

FNArena is proud about its track record and past achievements: Ten Years On

Share on FacebookTweet about this on TwitterShare on LinkedIn

Click to view our Glossary of Financial Terms